scholarly journals Molecular Detection of Oncogenic Human Papillomavirus (HPV) Genotypes in Vulva Cancers, Penile Cancers and Anal Cancers in Myanmar

2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 1s-1s
Author(s):  
Mu Mu Shwe ◽  
Hlaing Myat Thu ◽  
Khin Shwe Mar
Keyword(s):  
Human Papillomavirus ◽  
Conflicts Of Interest ◽  
Consensus Sequence ◽  
Restriction Enzymes ◽  
Cross Sectional ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Hpv Genotypes ◽  
Hpv 18 ◽  
Oncogenic Hpv

Abstract 12 A causal role for human papillomavirus (HPV) associated cancers of vulva, penile, and anus is supported by evidence from molecular and epidemiologic investigations. This study detected the oncogenic HPV genotypes in vulva cancers, penile cancers and anal cancers by a cross-sectional descriptive study in 2013. A total of 100 paraffin embedded biopsy tissues of histologically confirmed vulva cancers, penile cancers and anal cancers within past five years during 2008 and 2012 were studied. Those cases were 61 vulva cancers from Central Women Hospital, Yangon and 30 penile cancers and 9 anal cancers from Yangon General Hospital. HPV-DNA testing and genotyping were performed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Consensus sequence primer pairs within the E6 andE7 open reading were used to amplify oncogenic HPV genotypes (HPV-16,-18,-31,-33,-35,-52b,-58). Restriction enzymes were used for determination of specific HPV genotypes. HPV was identified in 36.1% of vulva cancers (22/61), 26.7% of penile cancers (8/30) and 44.4% of anal cancers (4/9). In vulva cancers, HPV-33 was the most common genotype (40.9%) followed by HPV-16 (31.8%), HPV-31 (22.7%), and HPV-18 (4.6%). In penile cancers, HPV-16 (62.5%) was the most common genotype followed by HPV-33 (25%) and HPV-18 (12.5%). Among anal cancers, the most frequent genotypes were HPV-16 (75%) and HPV-18 (25%). This study is the first report of evidence based oncogenic HPV genotypes in vulva cancers, penile cancers and anal cancers in Myanmar. This research provides the valuable information in understanding the burden of HPV associated cancers of the vulva, penile, and anus in Myanmar and the consideration of the effectiveness of prophylactic HPV vaccination in not only cervical cancer but also non-cervical cancers. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

scholarly journals High-Risk Human Papillomavirus (HR-HPV) Genotypes Among Women With Cervical Precancer and Cancer in Myanmar

2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 18s-19s
Author(s):  
Mu Mu Shwe ◽  
Kyi Kyi Nyunt ◽  
Khin Saw Aye ◽  
Hlaing Myat Thu ◽  
Hla Myat Mo Mo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Conflicts Of Interest ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Incidence And Mortality ◽  
Hpv Genotypes ◽  
Hpv 18

Abstract 11 In Myanmar, cervical cancer ranks as the first most frequent cancer among women aged between 15 to 44 years and Human Papillomavirus (HPV) vaccination program is not established yet. Information on HPV genotypes distribution in cervical cancer is crucial to predict the future impact of HPV vaccines. This study aimed to determine the HPV-DNA and genotypes among women with cervical pre-cancer and cancer in Myanmar. A cross-sectional descriptive study was performed in 169 women with cervical neoplasia during 2012 to 2014. After obtaining informed consent, cervical cells were collected from 134 women with cervical intraepithelial neoplasia (CIN) and 35 with squamous cell carcinoma (SCC) of the cervix attending Sanpya General Hospital, Yangon, and Central Women Hospital, Mandalay. HPV-DNA testing and genotyping was performed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). HR-HPV was identified in CINI (39.3%), CINII (58.6%), CINIII (66.7%), and SCC (77.1%). Overall, the most common genotypes were HPV-16 (68.1%), followed by HPV-31 (16.5%), HPV-18 (7.7%), HPV-58 (6.6%), and HPV-35 (1.1%). Among SCC, HPV-16 was the most common genotype (66.7%) followed by HPV-18 (14.8%), HPV-31 (11.1%), HPV-35 (3.7%), and HPV-58 (3.7%). In CINI, the most common genotype were HPV-16 (69.7%) followed by HPV-31 (21.2%), HPV-18 (6.1%) and HPV-58 (3.0%). In CINII, HPV-16 was most commonly determined (52.9%) followed by HPV-31 (23.5%), HPV-58 (17.6%), and HPV-18 (5.9%). In CINIII, HPV-16 was also the most common genotype (85.7%) followed by HPV-31 (7.1%) and HPV-58 (7.1%). Vaccine preventable genotype, HPV-16 was the most common genotype in Myanmar. This study highlighted that the establishment of National HPV vaccination program is needed to reduce the incidence and mortality of cervical cancer in Myanmar.[Table: see text][Table: see text] AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

scholarly journals Post HocAnalysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

2014 ◽  
Vol 22 (2) ◽  
pp. 235-244 ◽  
Author(s):  
Frank Struyf ◽  
Brigitte Colau ◽  
Cosette M. Wheeler ◽  
Paulo Naud ◽  
Suzanne Garland ◽  
...  
Keyword(s):  
Hpv 16 ◽  
Hpv Dna ◽  
Persistent Infections ◽  
Human Papillomavirus Type 16 ◽  
Specific Pcr ◽  
Hpv Genotypes ◽  
Hpv Types ◽  
Testing Algorithm ◽  
Hpv 18 ◽  
Oncogenic Hpv

ABSTRACTThe efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV in thePapillomaTrial againstCancerin YoungAdults (PATRICIA) was evaluated using a combination of the broad-spectrum L1-based SPF10PCR-DNA enzyme immunoassay (DEIA)/line probe assay (LiPA25) system with type-specific PCRs for HPV-16 and -18. Broad-spectrum PCR assays may underestimate the presence of HPV genotypes present at relatively low concentrations in multiple infections, due to competition between genotypes. Therefore, samples were retrospectively reanalyzed using a testing algorithm incorporating the SPF10PCR-DEIA/LiPA25plus a novel E6-based multiplex type-specific PCR and reverse hybridization assay (MPTS12 RHA), which permits detection of a panel of nine oncogenic HPV genotypes (types 16, 18, 31, 33, 35, 45, 52, 58, and 59). For the vaccine against HPV types 16 and 18, there was no major impact on estimates of vaccine efficacy (VE) for incident or 6-month or 12-month persistent infections when the MPTS12 RHA was included in the testing algorithm versus estimates with the protocol-specified algorithm. However, the alternative testing algorithm showed greater sensitivity than the protocol-specified algorithm for detection of some nonvaccine oncogenic HPV types. More cases were gained in the control group than in the vaccine group, leading to higher point estimates of VE for 6-month and 12-month persistent infections for the nonvaccine oncogenic types included in the MPTS12 RHA assay (types 31, 33, 35, 45, 52, 58, and 59). Thispost hocanalysis indicates that the per-protocol testing algorithm used in PATRICIA underestimated the VE against some nonvaccine oncogenic HPV types and that the choice of the HPV DNA testing methodology is important for the evaluation of VE in clinical trials. (This study has been registered at ClinicalTrials.gov under registration no. NCT00122681.)

Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix

2007 ◽  
Vol 17 (6) ◽  
pp. 1307-1313 ◽  
Author(s):  
S. Y. Tong ◽  
Y. S. Lee ◽  
J. S. Park ◽  
S. E. Namkoong
Keyword(s):  
Human Papillomavirus ◽  
Prognostic Significance ◽  
Rank Test ◽  
Lymph Node Status ◽  
Clinical Implications ◽  
Specific Sequence ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Cervical Carcinomas ◽  
Hpv 18

The clinical implications of specific human papillomavirus (HPV) types in invasive cervical carcinomas are only now beginning to be appreciated. The objective of this study was to determine the clinical implications and prognostic value of the HPV genotype in cervical carcinomas. In this study, we employed an HPV DNA chip to detect the type-specific sequence of HPV from cervical swabs taken from women with biopsy-proven neoplastic lesions of the cervix. We divided the patients into four groups: HPV-negative, HPV-16-related, HPV-18-related, and intermediate risk type–related. Associations with clinicopathologic data (stage, histologic type, lymph node status, parametrial invasion, lymphvascular space invasion, tumor size, vaginal involvement) and overall survival were assessed. HPV DNA was detected in 81.4% of the patients, and 19.0% harbored multiple HPV variants. HPV-16-related was the predominant type and was detected in 47.4% (46/97) of the patients. The HPV-16-related types were detected more frequently in patients with squamous cell carcinomas, whereas the HPV-18-related types were more prevalent in cases of adenocarcinomas and adenosquamous carcinomas (P< 0.05). Otherwise, no significant correlations were detected between the HPV genotype and any other clinicopathologic parameters. After a median follow-up of 30 months, the 5-year survival rate was lower in the HPV-18-related patients, but this difference was not found to be statistically significant, according to the results of the log-rank test. We conclude that neither the presence nor type of HPV DNA bears any prognostic significance in cases of cervical carcinoma.

scholarly journals Genotypes distribution of human papillomavirus in cervical samples of Ecuadorian women

2016 ◽  
Vol 19 (1) ◽  
pp. 160-166 ◽  
Author(s):  
Gustavo David García Muentes ◽  
Lindsay Karen García Rodríguez ◽  
Ramiro Israel Burgos Galarraga ◽  
Franklin Almeida Carpio ◽  
Juan Carlos Ruiz Cabezas
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Gynecological Cancer ◽  
Hpv Infection ◽  
Multiple Infections ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Hpv 18

ABSTRACT: Introduction: Human papillomavirus (HPV) is considered a necessary causative agent for developing oropharyngeal, anal and cervical cancer. Among women in Ecuadorian population, cervical cancer ranks as the second most common gynecological cancer. Not many studies about HPV burden have been published in Ecuador, and genotypes distribution has not been established yet. The little data available suggest the presence of other genotypes different than 16 and 18. Objectives: In the present study, we attempt to estimate the prevalence of HPV 16, HPV 18 and other 35 genotypes among Ecuadorian women undergoing cervical cancer screening. The overall prevalence of HPV infection was also estimated. Methods: Routine cervical samples were analyzed using Linear Array(r) HPV Genotyping test (Roche). Results: A total of 1,581 cervical samples obtained from Ecuadorian women undergoing cervical cancer screening were included in this study. HPV DNA was detected in 689 cervical samples (43.58%). Of these samples, 604 (38.20%) were positive for a single HPV genotype, while another 85 (5.37%) samples were positive for multiple HPV types. Genotype 16 (5.50%) resulted in the most frequently detected type in both single and multiple infections. HPV 33 (4.55%) and HPV 11 (3.80%) occupied the second and the third place in frequency among all detected genotypes. Conclusions: Viral genotypes different from HPV 16 and HPV 18 are frequently detected among Ecuadorian women. The overall prevalence of HPV resulted higher than the one reported in other South American countries with a greater burden in the second and third decades of life.

Human papillomavirus genotyping using HPV DNA chip analysis in Korean women

2007 ◽  
Vol 17 (2) ◽  
pp. 497-501 ◽  
Author(s):  
H. S. Lee ◽  
K. M. Kim ◽  
S. M. Kim ◽  
Y. D. Choi ◽  
J. H. Nam ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Cervical Neoplasia ◽  
Dna Chip ◽  
Korean Women ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Hpv Genotypes ◽  
High Risk Hpv ◽  
Chip Analysis

This study was designed to investigate the genotypes of human papillomavirus (HPV) in Korean women who had abnormal cervical cytology and to evaluate the clinical accuracy of HPV DNA chip analysis for the diagnosis of cervical neoplasia. Liquid-based cytology preparations, HPV DNA chip analysis, and cervical biopsy were performed in 2358 women. High-risk HPV was identified in 23.5% of 1650 histologically confirmed normal samples (including cervicitis and squamous metaplasia) and in 81.8% of 708 samples with cervical intraepithelial neoplasia (CIN) and carcinoma (P< 0.01). The major prevalent high-risk HPV genotypes in 381 samples of CIN II/III were HPV-16, -58, -33, and -31, in order of prevalence rate (average overall, 78.0%), and HPV-16, -18, -58, and -33 (average overall, 81.2%) in 133 samples of squamous cell carcinoma (SCC). The infection rate of HPV-16 was significantly higher than that of other high-risk HPV genotypes in all normal, CIN, and SCC cases (P< 0.01) and increased with more advanced squamous cervical lesions (P< 0.01). The detection accuracy of high-risk HPV using HPV DNA chip analysis for CIN II or worse was as follows: sensitivity 84% (81–87%), specificity 72% (70–74%), positive predictive value 47% (44–50%), and negative predictive value 94% (92–95%). These results suggest that HPV DNA chip analysis may be a reliable diagnostic tool for the detection of cervical neoplasia and that there are geographic differences in the distribution of high-risk HPV genotypes.

scholarly journals Genetic diversity in L1 gene of human papillomavirus variants in individuals with cervical cancer with and without human immunodeficiency virus in Botswana and Kenya

2021 ◽  
Author(s):  
Leabaneng Tawe ◽  
Wonderful T. Choga ◽  
Giacomo M. Paganotti ◽  
Ontlametse T. Bareng ◽  
Tlhalefo D. Ntereke ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Genomic Diversity ◽  
P Value ◽  
Hpv 16 ◽  
Nucleotide Variability ◽  
Hpv Genotypes ◽  
Living With Hiv ◽  
Hpv 18

Abstract Background The variation of human papillomavirus (HPV) genotypes shapes the risks of cervical cancer and these variations are not well defined in Africa. Nucleotide changes within the L1 gene, nucleotide variability, and phylogeny were explored in relation to HIV in samples from Botswana and Kenya. Methods A total of 98 HPV-positive cervical samples were sequenced to identify different HPV variants. Phylogenetic inferences were used to determine HPV genotypes and investigate the clustering of sequences between women living with HIV (WLWHIV) and -women not living with HIV (WNLWHIV). Results Out of 98 generated sequences, 83.7% (82/98) participants had high-risk(HR) HPV genotypes while 16.3% (16/98) had low-risk (LR) HPV genotypes. Among participants with HR-HPV genotypes, 47.6% (39/82) were coinfected with HIV. The prevalence of HR-HPV genotypes was statistically higher in the Botswana population compared to Kenya (p-value < 0.001). Multiple amino acid mutations were identified in both countries. Genetic diversity differed considerably among WLWHIV and WNLWHIV. The mean pairwise distances between HPV-16 between HIV and HIV/HPV as well as for HPV-18 were statistically significant. Six (6) new deleterious mutations were identified in the HPV genotypes based on the sequencing of the L1 region, HPV-16 (L441P, S343P), HPV-18 (S424P), HPV-45 (Q366H, Y365F), and HPV-84 (F458L). The majority of the patients with these mutations were co-infected with HIV. Conclusions Genomic diversity and different genomic variants of HPV sequences were demonstrated. Candidate novel mutations within the L1 gene were identified in both countries which can be further investigated using functional assays.

Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery

2004 ◽  
Vol 14 (4) ◽  
pp. 639-649 ◽  
Author(s):  
H. J. Huang ◽  
S. L. Huang ◽  
C. Y. Lin ◽  
R. W. Lin ◽  
F. Y. Chao ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Human Papillomavirus ◽  
Cervical Carcinoma ◽  
Radical Surgery ◽  
Chain Reaction ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Hpv Genotyping ◽  
Polymerase Chain ◽  
Hpv 18

The aim of this study was to evaluate the accuracy of human papillomavirus (HPV) genotyping by a polymerase chain reaction (PCR)-based genechip method and to determine the prognostic value of HPV genotype in bulky stage IB or IIA cervical carcinoma treated with neoadjuvant chemotherapy (NAC) and radical surgery. A total of 149 patients had adequate tissue for the study. The SPF1/GP6+ primers were used to amplify a 184 bp fragment. The amplimers were submitted for direct sequencing and hybridization with a genechip using revert-blot detection of 39 types of HPV DNA in a single reaction. Two runs of PCR with respective hybridization were performed for each tumor. The complete concordance of HPV genotyping was 80.5% (120/149) of the paired genechip results. The kappa coefficient was 0.634 (P < 0.0001). HPV DNA sequences were detected in 100% of the specimens, among which 67.8% harbored single type and 32.2% contained multiple types. HPV-16 was detected in 98.7%, HPV-18 in 22.8%, HPV-31 in 0.7%, HPV-45 in 1.3%, HPV-52 in 2.0%, HPV-58 in 6.7%, HPV-59 in 4.7%, and HPV-67 in 0.7%. In multivariate analyses, the HPV genotype [HPV-18 or HPV-16 and HPV-18 only versus all others: relative risk (RR), 2.33; 95% CI, 1.17–4.64; P = 0.016] and pre-NAC tumor size (>5 versus ≤5 cm: RR, 2.25; 95% CI, 1.13–4.48; P = 0.021) were significantly related to overall survival. This PCR-based genechip method is sensitive and reproducible for HPV genotyping. The association of HPV-18 or HPV-16 and HPV-18 with poor outcome in cervical carcinoma treated with NAC plus radical surgery is confirmed.

scholarly journals Ανίχνευση του ιού Human Papillomavirus (HPV) στον καρκίνο του πνεύμονα

2014 ◽  
Author(s):  
Εμμανουέλα Σαρχιανάκη
Keyword(s):  
Human Papillomavirus ◽  
Human Papilloma Virus ◽  
Real Time ◽  
Real Time Pcr ◽  
Hpv 16 ◽  
Papilloma Virus ◽  
Hpv Dna ◽  
Hpv 18

Παρά το ότι ο ρόλος του ιού των ανθρωπίνων θηλωμάτων ( Human Papilloma virus, HPV) στην εμφάνιση του καρκίνου του τραχήλου της μήτρας είναι καλά τεκμηριωμένος, ο ρόλος του HPV στην καρκινογένεση του πνεύμονα παραμένει αμφιλεγόμενος. Η συχνότητα ανίχνευσης του HPV DNA υπόκεινται σε ευρεία διακύμανση, από 0 έως 100 %. Αυτό εν μέρει οφείλεται στην τεχνική ανίχνευσης που χρησιμοποιήθηκε. Για να διευκρινίσουμε την επίδραση της HPV λοίμωξης στο πνευμονικό παρέγχυμα, αναλύσαμε 100 δείγματα από μη-μικροκυτταρικό καρκίνο πνεύμονα (39 πλακώδη καρκινώματα, 50 αδενοκαρκινώματα, 5 αδενοπλακώδη, 5 αδιαφοροποίητα και 1 μεγαλοκυτταρικό) από την περιοχή της Κρήτης στην Ελλάδα. Ως αρνητικός μάρτυρας χρησιμοποιήθηκαν 16 δείγματα υγειούς πνευμονικού ιστού. Έγινε εκχύλιση DNA από 100 τομές μονιμοποιημένες σε παραφίνη που πάρθηκαν από ασθενείς με μη-μικροκυτταρικό καρκίνο του πνεύμονα. Τα δείγματα εξετάσθηκαν για την παρουσία του HPV DNA με την τεχνική της Real Time PCR χρησιμοποιώντας τους γενικούς εκκινητές GP5+/GP6+. Επιπλέον, τα HPV θετικά δείγματα υπεβλήθησαν σε γονοτυπική ανάλυση. Σε αντιδιαστολή με την απουσία του ιϊκού γονιδιώματος στα δείγματα ελέγχου, HPV DNA ανιχνεύθηκε σε 19 από τα 100 εξετασθέντα δείγματα (19%). Συγκεκριμένα, 4 πλακώδη καρκινώματα, 12 αδενοκαρκινώματα, 1 αδενοπλακώδες και 2 αδιαφοροποίητα ήταν HPV θετικά. Η κατανομή των γονοτύπων του HPV ήταν η ακόλουθη : HPV 16 : 8 περιστατικά (42,1 %) , HPV 11 : 3 περιστατικά (15,8 %) , HPV 6 : 1 περιστατικό (5,2 %) , HPV 33 : 2 περιστατικά (10,5 %) , HPV 31 : 2 περιστατικά (10,5 %) και HPV 18 : 2 περιστατικά (10,5 %) . Η παρουσία του HPV στα δείγματα από καρκίνο παρέχει στοιχεία για τον πιθανό ρόλο του στο μη-μικροκυτταρικό καρκίνο του πνεύμονα και υποδεικνύει την ανάγκη για περαιτέρω έρευνα στο συγκεκριμένο πεδίο.

Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji

Sexual Health ◽  
2011 ◽  
Vol 8 (3) ◽  
pp. 338 ◽  
Author(s):  
Sepehr N. Tabrizi ◽  
Irwin Law ◽  
Eka Buadromo ◽  
Matthew P. Stevens ◽  
James Fong ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Genotype Distribution ◽  
Limited Information ◽  
Cross Sectional ◽  
Detection Rates ◽  
Hpv Dna ◽  
Hpv Genotypes ◽  
Sectional Analysis

Background There is currently limited information about human papillomavirus (HPV) genotype distribution in women in the South Pacific region. This study’s objective was to determine HPV genotypes present in cervical cancer (CC) and precancers (cervical intraepithelial lesion (CIN) 3) in Fiji. Methods: Cross-sectional analysis evaluated archival CC and CIN3 biopsy samples from 296 women of Melanesian Fijian ethnicity (n = 182, 61.5%) and Indo-Fijian ethnicity (n = 114, 38.5%). HPV genotypes were evaluated using the INNO-LiPA assay in archival samples from CC (n = 174) and CIN3 (n = 122) among women in Fiji over a 5-year period from 2003 to 2007. Results: Overall, 99% of the specimens tested were HPV DNA-positive for high-risk genotypes, with detection rates of 100%, 97.4% and 100% in CIN3, squamous cell carcinoma (SCC) and adenosquamous carcinoma biopsies, respectively. Genotypes 16 and 18 were the most common (77%), followed by HPV 31 (4.3%). Genotype HPV 16 was the most common identified (59%) in CIN3 specimens, followed by HPV 31 (9%) and HPV 52 (6.6%). Multiple genotypes were detected in 12.5–33.3% of specimens, depending on the pathology. Conclusion: These results indicated that the two most prevalent CC-associated HPV genotypes in Fiji parallel those described in other regions worldwide, with genotype variations thereafter. These data suggest that the currently available bivalent and quadrivalent HPV vaccines could potentially reduce cervical cancers in Fiji by over 80% and reduce precancers by at least 60%.

scholarly journals Molecular detection of oncogenic subtypes of human papillomavirus (HPV) in a group of women in the Amazon region of Brazil

2020 ◽  
Vol 42 ◽  
pp. e50005
Author(s):  
Alessandra Silva e Silva ◽  
Cláudia Giuliano Bica ◽  
Aniúsca Vieira ◽  
Cleiton Fantin
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Genetic Material ◽  
Hpv Infection ◽  
Cervical Cancer Prevention ◽  
Eligibility Criteria ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Human Papillomavirus 16 ◽  
Hpv 18

The natural history of cervical cancer is strongly related to the presence of human papillomavirus (HPV) infection, with its relationship with cervical cancer being a matter of concern. It is estimated that 70% of all cervical cancers worldwide are caused by HPV 16 and 18. Accordingly, the present study aimed to contribute to the identification of HPV subtypes circulating in a group of women of Manaus-Brazil.  Cervical samples were collected from 49 women, following the eligibility criteria of the study, and DNA was then extracted from the samples, which were analyzed for the presence of the virus in the genetic material through the polymerase chain reaction (PCR) using generic primers (GP05/06). Finally, identification of the viral subtypes was performed using specific primers for the detection of the main subtypes already examined (16 and 18). Positive HPV DNA was detected in 100% of the samples included in the study. Human papillomavirus 16 was the most prevalent subtype in the majority of lesions, accounting for 29 (59.2%) of the positive cases, and HPV 18 was detected in four (8.2%) women. In these 4 cases there was co-infection, with the presence of both HPV 18 and HPV 16. Therefore, 40.8% (20 cases) in which HPV DNA was detected presented infection with other subtypes of HPV not included in the study. This data has clinical implications related to cervical cancer prevention, as the current prophylactic HPV vaccines are only effective against high-risk HPV 16 and 18 subtypes.

Sign in / Sign up

Export Citation Format

Share Document